Does the media refer more to IRWD or ABBV?

In the previous week, AbbVie had 137 more articles in the media than Ironwood Pharmaceuticals. MarketBeat recorded 140 mentions for AbbVie and 3 mentions for Ironwood Pharmaceuticals. AbbVie's average media sentiment score of 1.01 beat Ironwood Pharmaceuticals' score of -0.06 indicating that AbbVie is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Ironwood Pharmaceuticals 1 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral AbbVie 90 Very Positive mention(s) 18 Positive mention(s) 27 Neutral mention(s) 3 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer IRWD or INVA?

In the previous week, Innoviva had 10 more articles in the media than Ironwood Pharmaceuticals. MarketBeat recorded 13 mentions for Innoviva and 3 mentions for Ironwood Pharmaceuticals. Ironwood Pharmaceuticals' average media sentiment score of -0.06 beat Innoviva's score of -0.52 indicating that Ironwood Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Ironwood Pharmaceuticals 1 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Innoviva 0 Very Positive mention(s) 2 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Negative

Does the media favor IRWD or NVAX?

In the previous week, Novavax had 4 more articles in the media than Ironwood Pharmaceuticals. MarketBeat recorded 7 mentions for Novavax and 3 mentions for Ironwood Pharmaceuticals. Novavax's average media sentiment score of 0.41 beat Ironwood Pharmaceuticals' score of -0.06 indicating that Novavax is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Ironwood Pharmaceuticals 1 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Novavax 0 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 3 Negative mention(s) 1 Very Negative mention(s) Neutral

Does the media refer more to IRWD or ZBIO?

In the previous week, Ironwood Pharmaceuticals and Ironwood Pharmaceuticals both had 3 articles in the media. Zenas BioPharma's average media sentiment score of 0.90 beat Ironwood Pharmaceuticals' score of -0.06 indicating that Zenas BioPharma is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Ironwood Pharmaceuticals 1 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Zenas BioPharma 2 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Ironwood Pharmaceuticals (IRWD) Competitors

$3.91 +0.05 (+1.30%)

Closing price 04:00 PM Eastern

Extended Trading

$3.92 +0.00 (+0.13%)

As of 07:06 PM Eastern

Compare

IRWD vs. ABBV, BCRX, INVA, NVAX, and ZBIO

Should you buy Ironwood Pharmaceuticals stock or one of its competitors? MarketBeat compares Ironwood Pharmaceuticals with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Ironwood Pharmaceuticals include AbbVie (ABBV), BioCryst Pharmaceuticals (BCRX), Innoviva (INVA), Novavax (NVAX), and Zenas BioPharma (ZBIO). These companies are all part of the "medical" sector.

How does Ironwood Pharmaceuticals compare to AbbVie?

Ironwood Pharmaceuticals (NASDAQ:IRWD) and AbbVie (NYSE:ABBV) are both medical companies, but which is the better stock? We will compare the two companies based on the strength of their earnings, risk, institutional ownership, media sentiment, profitability, dividends, analyst recommendations and valuation.

70.2% of AbbVie shares are owned by institutional investors. 9.3% of Ironwood Pharmaceuticals shares are owned by insiders. Comparatively, 0.1% of AbbVie shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Ironwood Pharmaceuticals has a beta of 0.25, meaning that its stock price is 75% less volatile than the broader market. Comparatively, AbbVie has a beta of 0.32, meaning that its stock price is 68% less volatile than the broader market.

In the previous week, AbbVie had 137 more articles in the media than Ironwood Pharmaceuticals. MarketBeat recorded 140 mentions for AbbVie and 3 mentions for Ironwood Pharmaceuticals. AbbVie's average media sentiment score of 1.01 beat Ironwood Pharmaceuticals' score of -0.06 indicating that AbbVie is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Ironwood Pharmaceuticals	1 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
AbbVie	90 Very Positive mention(s)	18 Positive mention(s)	27 Neutral mention(s)	3 Negative mention(s)	0 Very Negative mention(s)	Positive

Ironwood Pharmaceuticals currently has a consensus target price of $6.23, suggesting a potential upside of 59.42%. AbbVie has a consensus target price of $253.81, suggesting a potential upside of 8.10%. Given Ironwood Pharmaceuticals' higher probable upside, equities research analysts clearly believe Ironwood Pharmaceuticals is more favorable than AbbVie.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Ironwood Pharmaceuticals	1 Sell rating(s)	3 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.43
AbbVie	0 Sell rating(s)	6 Hold rating(s)	16 Buy rating(s)	3 Strong Buy rating(s)	2.88

Ironwood Pharmaceuticals has a net margin of 28.26% compared to AbbVie's net margin of 5.79%. Ironwood Pharmaceuticals' return on equity of -39.65% beat AbbVie's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Ironwood Pharmaceuticals	28.26%	-39.65%	26.54%
AbbVie	5.79%	-576.45%	13.39%

AbbVie has higher revenue and earnings than Ironwood Pharmaceuticals. Ironwood Pharmaceuticals is trading at a lower price-to-earnings ratio than AbbVie, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Ironwood Pharmaceuticals	$296.15M	2.15	$24.02M	$0.60	6.52
AbbVie	$61.16B	6.78	$4.23B	$2.03	115.66

Summary

AbbVie beats Ironwood Pharmaceuticals on 12 of the 17 factors compared between the two stocks.

How does Ironwood Pharmaceuticals compare to BioCryst Pharmaceuticals?

BioCryst Pharmaceuticals (NASDAQ:BCRX) and Ironwood Pharmaceuticals (NASDAQ:IRWD) are both medical companies, but which is the superior business? We will compare the two companies based on the strength of their earnings, profitability, media sentiment, analyst recommendations, institutional ownership, risk, valuation and dividends.

Ironwood Pharmaceuticals has a net margin of 28.26% compared to BioCryst Pharmaceuticals' net margin of -51.71%. Ironwood Pharmaceuticals' return on equity of -39.65% beat BioCryst Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
BioCryst Pharmaceuticals	-51.71%	-76.36%	60.12%
Ironwood Pharmaceuticals	28.26%	-39.65%	26.54%

In the previous week, Ironwood Pharmaceuticals had 2 more articles in the media than BioCryst Pharmaceuticals. MarketBeat recorded 3 mentions for Ironwood Pharmaceuticals and 1 mentions for BioCryst Pharmaceuticals. BioCryst Pharmaceuticals' average media sentiment score of 0.00 beat Ironwood Pharmaceuticals' score of -0.06 indicating that BioCryst Pharmaceuticals is being referred to more favorably in the media.

Company	Overall Sentiment
BioCryst Pharmaceuticals	Neutral
Ironwood Pharmaceuticals	Neutral

BioCryst Pharmaceuticals currently has a consensus price target of $20.70, indicating a potential upside of 107.54%. Ironwood Pharmaceuticals has a consensus price target of $6.23, indicating a potential upside of 59.42%. Given BioCryst Pharmaceuticals' stronger consensus rating and higher probable upside, equities analysts plainly believe BioCryst Pharmaceuticals is more favorable than Ironwood Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
BioCryst Pharmaceuticals	0 Sell rating(s)	3 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.75
Ironwood Pharmaceuticals	1 Sell rating(s)	3 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.43

BioCryst Pharmaceuticals has a beta of 0.57, indicating that its share price is 43% less volatile than the broader market. Comparatively, Ironwood Pharmaceuticals has a beta of 0.25, indicating that its share price is 75% less volatile than the broader market.

85.9% of BioCryst Pharmaceuticals shares are held by institutional investors. 3.8% of BioCryst Pharmaceuticals shares are held by insiders. Comparatively, 9.3% of Ironwood Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

BioCryst Pharmaceuticals has higher revenue and earnings than Ironwood Pharmaceuticals. BioCryst Pharmaceuticals is trading at a lower price-to-earnings ratio than Ironwood Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
BioCryst Pharmaceuticals	$874.84M	2.90	$263.86M	-$1.78	N/A
Ironwood Pharmaceuticals	$296.15M	2.15	$24.02M	$0.60	6.52

Summary

BioCryst Pharmaceuticals beats Ironwood Pharmaceuticals on 10 of the 17 factors compared between the two stocks.

How does Ironwood Pharmaceuticals compare to Innoviva?

Ironwood Pharmaceuticals (NASDAQ:IRWD) and Innoviva (NASDAQ:INVA) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their analyst recommendations, valuation, profitability, media sentiment, risk, dividends, earnings and institutional ownership.

Innoviva has higher revenue and earnings than Ironwood Pharmaceuticals. Innoviva is trading at a lower price-to-earnings ratio than Ironwood Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Ironwood Pharmaceuticals	$296.15M	2.15	$24.02M	$0.60	6.52
Innoviva	$411.33M	4.24	$271.17M	$6.01	3.93

Ironwood Pharmaceuticals has a beta of 0.25, indicating that its share price is 75% less volatile than the broader market. Comparatively, Innoviva has a beta of 0.35, indicating that its share price is 65% less volatile than the broader market.

Ironwood Pharmaceuticals presently has a consensus target price of $6.23, indicating a potential upside of 59.42%. Innoviva has a consensus target price of $36.20, indicating a potential upside of 53.13%. Given Ironwood Pharmaceuticals' higher probable upside, equities research analysts clearly believe Ironwood Pharmaceuticals is more favorable than Innoviva.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Ironwood Pharmaceuticals	1 Sell rating(s)	3 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.43
Innoviva	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.57

Innoviva has a net margin of 119.89% compared to Ironwood Pharmaceuticals' net margin of 28.26%. Innoviva's return on equity of 33.33% beat Ironwood Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Ironwood Pharmaceuticals	28.26%	-39.65%	26.54%
Innoviva	119.89%	33.33%	22.67%

In the previous week, Innoviva had 10 more articles in the media than Ironwood Pharmaceuticals. MarketBeat recorded 13 mentions for Innoviva and 3 mentions for Ironwood Pharmaceuticals. Ironwood Pharmaceuticals' average media sentiment score of -0.06 beat Innoviva's score of -0.52 indicating that Ironwood Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Ironwood Pharmaceuticals	1 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Innoviva	0 Very Positive mention(s)	2 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Negative

99.1% of Innoviva shares are held by institutional investors. 9.3% of Ironwood Pharmaceuticals shares are held by insiders. Comparatively, 2.0% of Innoviva shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Summary

Innoviva beats Ironwood Pharmaceuticals on 11 of the 17 factors compared between the two stocks.

How does Ironwood Pharmaceuticals compare to Novavax?

Ironwood Pharmaceuticals (NASDAQ:IRWD) and Novavax (NASDAQ:NVAX) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their institutional ownership, dividends, media sentiment, risk, earnings, profitability, analyst recommendations and valuation.

Ironwood Pharmaceuticals has a net margin of 28.26% compared to Novavax's net margin of -14.73%. Novavax's return on equity of -14.82% beat Ironwood Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Ironwood Pharmaceuticals	28.26%	-39.65%	26.54%
Novavax	-14.73%	-14.82%	1.23%

Ironwood Pharmaceuticals has a beta of 0.25, meaning that its share price is 75% less volatile than the broader market. Comparatively, Novavax has a beta of 2.45, meaning that its share price is 145% more volatile than the broader market.

In the previous week, Novavax had 4 more articles in the media than Ironwood Pharmaceuticals. MarketBeat recorded 7 mentions for Novavax and 3 mentions for Ironwood Pharmaceuticals. Novavax's average media sentiment score of 0.41 beat Ironwood Pharmaceuticals' score of -0.06 indicating that Novavax is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Ironwood Pharmaceuticals	1 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Novavax	0 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	3 Negative mention(s)	1 Very Negative mention(s)	Neutral

53.0% of Novavax shares are owned by institutional investors. 9.3% of Ironwood Pharmaceuticals shares are owned by company insiders. Comparatively, 1.6% of Novavax shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Ironwood Pharmaceuticals presently has a consensus price target of $6.23, suggesting a potential upside of 59.42%. Novavax has a consensus price target of $13.00, suggesting a potential upside of 46.15%. Given Ironwood Pharmaceuticals' stronger consensus rating and higher probable upside, equities analysts clearly believe Ironwood Pharmaceuticals is more favorable than Novavax.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Ironwood Pharmaceuticals	1 Sell rating(s)	3 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.43
Novavax	3 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.22

Novavax has higher revenue and earnings than Ironwood Pharmaceuticals. Novavax is trading at a lower price-to-earnings ratio than Ironwood Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Ironwood Pharmaceuticals	$296.15M	2.15	$24.02M	$0.60	6.52
Novavax	$1.12B	1.30	$440.30M	-$0.58	N/A

Summary

Ironwood Pharmaceuticals beats Novavax on 9 of the 17 factors compared between the two stocks.

How does Ironwood Pharmaceuticals compare to Zenas BioPharma?

Ironwood Pharmaceuticals (NASDAQ:IRWD) and Zenas BioPharma (NASDAQ:ZBIO) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, profitability, analyst recommendations, risk, valuation, institutional ownership, earnings and media sentiment.

Ironwood Pharmaceuticals has higher revenue and earnings than Zenas BioPharma. Zenas BioPharma is trading at a lower price-to-earnings ratio than Ironwood Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Ironwood Pharmaceuticals	$296.15M	2.15	$24.02M	$0.60	6.52
Zenas BioPharma	$10M	137.62	-$377.74M	-$8.47	N/A

Ironwood Pharmaceuticals has a beta of 0.25, indicating that its share price is 75% less volatile than the broader market. Comparatively, Zenas BioPharma has a beta of -0.71, indicating that its share price is 171% less volatile than the broader market.

Ironwood Pharmaceuticals has a net margin of 28.26% compared to Zenas BioPharma's net margin of 0.00%. Ironwood Pharmaceuticals' return on equity of -39.65% beat Zenas BioPharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Ironwood Pharmaceuticals	28.26%	-39.65%	26.54%
Zenas BioPharma	N/A	-99.99%	-58.06%

In the previous week, Ironwood Pharmaceuticals and Ironwood Pharmaceuticals both had 3 articles in the media. Zenas BioPharma's average media sentiment score of 0.90 beat Ironwood Pharmaceuticals' score of -0.06 indicating that Zenas BioPharma is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Ironwood Pharmaceuticals	1 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Zenas BioPharma	2 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Ironwood Pharmaceuticals currently has a consensus target price of $6.23, indicating a potential upside of 59.42%. Zenas BioPharma has a consensus target price of $44.29, indicating a potential upside of 103.15%. Given Zenas BioPharma's stronger consensus rating and higher possible upside, analysts plainly believe Zenas BioPharma is more favorable than Ironwood Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Ironwood Pharmaceuticals	1 Sell rating(s)	3 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.43
Zenas BioPharma	1 Sell rating(s)	2 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.56

Summary

Ironwood Pharmaceuticals beats Zenas BioPharma on 9 of the 14 factors compared between the two stocks.

Get Ironwood Pharmaceuticals News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding IRWD and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

IRWD vs. The Competition

Export

Metric	Ironwood Pharmaceuticals	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$629.41M	$2.99B	$6.74B	$12.32B
Dividend Yield	N/A	1.78%	2.68%	5.88%
P/E Ratio	6.52	18.65	25.39	23.96
Price / Sales	2.15	341.96	530.17	107.90
Price / Cash	15.00	56.64	45.29	53.76
Price / Book	-2.43	4.14	10.76	6.41
Net Income	$24.02M	$64.45M	$3.56B	$337.14M
7 Day Performance	11.08%	1.34%	1.37%	-0.48%
1 Month Performance	-0.26%	0.95%	0.81%	0.49%
1 Year Performance	438.72%	24.33%	30.53%	28.16%

Ironwood Pharmaceuticals Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
IRWD Ironwood Pharmaceuticals	2.9427 of 5 stars	$3.91 +1.3%	$6.23 +59.4%	+473.2%	$629.41M	$296.15M	6.52	220
ABBV AbbVie	4.3481 of 5 stars	$221.42 -2.8%	$253.43 +14.5%	+27.8%	$402.35B	$61.16B	109.07	57,000	Trending News Dividend Announcement Analyst Forecast
BCRX BioCryst Pharmaceuticals	2.1941 of 5 stars	$9.06 +4.1%	$20.70 +128.5%	-6.1%	$2.21B	$874.84M	N/A	530	Options Volume
INVA Innoviva	3.7639 of 5 stars	$22.42 -1.4%	$36.20 +61.5%	+13.2%	$1.68B	$411.33M	3.73	100	Trending News Analyst Forecast Analyst Revision
NVAX Novavax	1.8499 of 5 stars	$9.21 +3.7%	$12.13 +31.7%	+42.6%	$1.46B	$1.12B	N/A	1,990	News Coverage

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:IRWD) was last updated on 6/24/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Ironwood Pharmaceuticals (IRWD) Competitors

IRWD vs. ABBV, BCRX, INVA, NVAX, and ZBIO

How does Ironwood Pharmaceuticals compare to AbbVie?

Summary

How does Ironwood Pharmaceuticals compare to BioCryst Pharmaceuticals?

Summary

How does Ironwood Pharmaceuticals compare to Innoviva?

Summary

How does Ironwood Pharmaceuticals compare to Novavax?

Summary

How does Ironwood Pharmaceuticals compare to Zenas BioPharma?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

IRWD vs. The Competition

Ironwood Pharmaceuticals Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Ironwood Pharmaceuticals (IRWD) Competitors

IRWD vs. ABBV, BCRX, INVA, NVAX, and ZBIO

How does Ironwood Pharmaceuticals compare to AbbVie?

Do insiders and institutionals have more ownership in IRWD or ABBV?

Which has more volatility and risk, IRWD or ABBV?

Does the media refer more to IRWD or ABBV?

Do analysts rate IRWD or ABBV?

Is IRWD or ABBV more profitable?

Which has preferable earnings and valuation, IRWD or ABBV?

Summary

How does Ironwood Pharmaceuticals compare to BioCryst Pharmaceuticals?

Is BCRX or IRWD more profitable?

Does the media favor BCRX or IRWD?

Do analysts rate BCRX or IRWD?

Which has more volatility & risk, BCRX or IRWD?

Do insiders & institutionals believe in BCRX or IRWD?

Which has higher earnings and valuation, BCRX or IRWD?

Summary

How does Ironwood Pharmaceuticals compare to Innoviva?

Which has stronger earnings & valuation, IRWD or INVA?

Which has more volatility & risk, IRWD or INVA?

Do analysts rate IRWD or INVA?

Is IRWD or INVA more profitable?

Does the media prefer IRWD or INVA?

Do institutionals & insiders hold more shares of IRWD or INVA?

Summary

How does Ironwood Pharmaceuticals compare to Novavax?

Is IRWD or NVAX more profitable?

Which has more volatility and risk, IRWD or NVAX?

Does the media favor IRWD or NVAX?

Do institutionals and insiders hold more shares of IRWD or NVAX?

Do analysts rate IRWD or NVAX?

Which has stronger earnings & valuation, IRWD or NVAX?

Summary

How does Ironwood Pharmaceuticals compare to Zenas BioPharma?

Which has higher valuation & earnings, IRWD or ZBIO?

Which has more volatility and risk, IRWD or ZBIO?

Is IRWD or ZBIO more profitable?

Does the media refer more to IRWD or ZBIO?

Do analysts rate IRWD or ZBIO?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

IRWD vs. The Competition

Ironwood Pharmaceuticals Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools